Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 14/20 | 0.39 |
| ▸ | AKT1 | P31749 | 8/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | WNT1 | P04628 | 2/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761098 | 1.00 | RPS6KB1 (0.39) | RPS6KB1AKT1DYRK1AWNT1CLK2 | |
| SCHEMBL30002581 | 0.86 | HCAR2 (0.36) | RPS6KB1AKT1DYRK1AWNT1TSHR | |
| SCHEMBL16516910 | 0.86 | HCAR2 (0.36) | RPS6KB1AKT1DYRK1AWNT1TSHR | |
| SCHEMBL38656719 | 0.83 | HDAC6 (0.37) | RPS6KB1AKT1DYRK1AWNT1CLK2 | |
| SCHEMBL1689038 | 0.80 | CYP1A2 (0.39) | TSHRJAK1KDM4E | |
| SCHEMBL30200851 | 0.77 | KDM4E (0.52) | KDM4E | |
| SCHEMBL5616257 | 0.77 | ALDH1A1 (0.43) | DYRK1AKDM4E | |
| SCHEMBL15109789 | 0.76 | PDPK1 (0.31) | KDM4E | |
| SCHEMBL15942802 | 0.75 | IKBKB (0.43) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL31398027 | 0.75 | DYRK1B (0.42) | DYRK1ACLK2JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3236943-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | claimed |
| WO-2016105582-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | NUNN PHILIP A (US) | 2016-06-30 | — | — | WO | claimed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | claimed |
| EP-1807429-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM, LLC (BM) | 2007-07-18 | — | — | EP | claimed |
| WO-2006047516-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2006-05-04 | — | — | WO | claimed |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| CN-108137607-B | Compounds and compositions suitable for treating NTRK-related disorders | 缆图药品公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-3341374-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | Blueprint Medicines Corporation (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3236943-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3233103-A1 | TREATMENT OF PEMPHIGUS | PRINCIPIA BIOPHARMA, INC. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017035354-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016105582-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | NUNN PHILIP A (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-3036230-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2016100914-A1 | TREATMENT OF PEMPHIGUS | GOURLAY STEVEN (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | RPS6KB1 78/4885AKT1 178/4885DYRK1A 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.